Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Truvada For PrEP Approval Reflects Limits Of REMS Assessments

Executive Summary

In approving the antiretroviral fixed-dose combination for pre-exposure prophylaxis, FDA is requiring Gilead to gather information about the development of viral resistance and compliance with HIV testing requirements “to the extent possible,” suggesting a willingness to be flexible on REMS assessments when the data may be hard to come by. Further clarity is expected from mandatory post-marketing studies.

Advertisement

Related Content

Two Indications, One REMS: FDA Panel Debates Restricted Access For Truvada In PrEP

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel